Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, given weekly to advanced solid tumor patients for 3 weeks

Cancer Science

Volumn 100, Issue 2, 2009, Pages 316-321

  Yamamoto, Nobuyuki ^a   Andoh, Masahiro ^a   Kawahara, Masaaki ^a   Fukuoka, Masahiro ^a   Niitani, Hisanobu ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; DOLASTATIN 10; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; NAVELBINE; SOBLIDOTIN; VINCRISTINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSTIPATION; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG STRUCTURE; DRUG WITHDRAWAL; FEMALE; HUMAN; JAPANESE; LEUKOPENIA; MALAISE; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MEAN RESIDENCE TIME; MICROTUBULE ASSEMBLY; MYALGIA; NAUSEA AND VOMITING; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; PROGNOSIS; REPEATED DRUG DOSE; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DEPSIPEPTIDES; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; OLIGOPEPTIDES; POLYMERIZATION; SURVIVAL RATE; TREATMENT OUTCOME; TUBULIN; TUBULIN MODULATORS;

EID: 58549093199     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.01023.x     Document Type: Article

References (23)

1. Miyazaki K, Kobayashi M, Natsume T et al. Synthesis and antitumor activity of novel dolastatin 10 analogs. Chem Pharm Bull 1995; 43: 1706-18.
2. Pettit GR, Kamano Y, Herald CL et al. The isolation and structure of a remarkable marine animal antineoplastic constituent: Dolastatin 10. J Am Chem Soc 1987; 109: 6883-5.
3. Watanabe J, Natsume T, Fujio N, Miyasaka K, Kobayashi M. Induction of apoptosis in human cancer cells by TZT-1027, an antimicrotubule agent. Apoptosis 2000; 5: 345-53.
4. Natsume T, Watanabe J, Tamaoki S, Fujio N, Miyasaka K, Kobayashi M. Characterization of the interaction of TZT-1027a potent antitumour agent, with tubulin. Jpn J Cancer Res 2000; 91: 737-47.
5. Fujita F, Koike M, Fujita M, Sakamoto Y, Tsukagoshi S. Antitumor effects of TZT-1027a novel dolastatin 10 derivative, on human tumor xenografts in nude mice. Jpn J Cancer Chemother 2000; 27: 451-8.
6. Hashiguchi N, Kubota T, Koh J et al. TZT-1027 elucidates antitumor activity through direct cytotoxicity and selective blockage of blood supply. Anticancer Res 2004; 24: 2201-8.
7. Natsume T, Watanabe J, Koh Y et al. Antitumor activity of TZT-1027 (soblidotin) against endothelial growth factor-secreting human lung cancer in vivo. Cancer Sci 2003; 94: 826-33.
8. Otani M, Natsume T, Watanabe JI et al. TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death. Jpn J Cancer Res 2000; 91: 837-44.
9. Ogawa T, Mimura Y, Isowa K et al. An antimicrotubule agent, TZT-1027, does not induce neuropathologic alterations which are detected after administration of vincristine or paclitaxel in animal models. Toxicol Lett 2001; 121: 97-106.
10. Niitani H, Hasegawa K, Furuse K, Fukuoka M, Horikoshi N, Kudoh S. Phase I studies of TZT-1027a novel inhibitor of tubulin polymerization (Abstract). Ann Oncol 1998; 9 (Suppl. 2): 360.
11. Shibuya M. Adverse drug reaction criteria of the Japan Society for Cancer Therapy. Gan to Kagaku Ryoho 1997; 24: 2036-41.
12. Furue H, Hara Y, Imai Y et al. Criteria for the evaluation of the clinical effects of solid cancer chemotherapy. J Jpn Soc Cancer Ther 1993; 28(2): 101-30.
13. Mross K, Herbst K, Berdel WE et al. Phase I clinical and pharmacokinetic study of LU103793 (Cemadotin hydrochloride) as an intravenous bolus injection in patients with metastatic solid tumors. Onkologie 1996; 19: 490-5.
14. Cunningham C, Appleman LJ, Kirvan-Visovatti M et al. Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2005; 11: 7825-33.
15. Ebbinghaus S, Rubin E, Hersh E et al. A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2005; 11: 7807-78.
16. Madden T, Tran HT, Beck D et al. Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res 2000; 6: 1293-301.
17. Pilot HC, McElroy EA, Reid JM et al. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors. Clin Cancer Res 1999; 5: 525-31.
18. de Jonge MJ, van der Gaast A, Planting AS et al. Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors. Clin Cancer Res 2005; 11: 3806-13.
19. Kenji T, Kazuhiko N, Takayasu K et al. Phase I study of TZT-1027a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses. Cancer Chemother Pharmacol 2007; 60: 285-93.
20. Junichi W, Tsugitaka N, Motohiro K. Antivascular effects of TZT-1027 (Soblidotin) on murine Colon26 adenocarcinoma. Cancer Sci 2006; 97: 1410-16.
21. Tsugitaka N, Junichi W, Kenji O, Kazuhiko Y, Motohiro K. Tumor-specific antivascular effect of TZT-1027 (Soblidotin) elucidated by magnetic resonance imaging and confocal laser scanning microscopy. Cancer Sci 2007; 98: 598-604.
22. Akashi Y, Okamoto I, Suzuki M et al. The novel microtubule-interfering agent TZT-1027 enhances the anticancer effect of radiation in vitro and in vivo. Br J Cancer 2007; 96: 1532-9.
23. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.